Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Research & Development (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Research & Development for 7 consecutive years, with $15.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 31.61% to $15.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.1 million, a 11.49% decrease, with the full-year FY2025 number at $56.1 million, down 11.49% from a year prior.
  • Research & Development was $15.4 million for Q4 2025 at Fulcrum Therapeutics, up from $14.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $25.0 million in Q2 2022 to a low of $11.7 million in Q4 2024.
  • A 5-year average of $16.9 million and a median of $17.2 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 43.97% in 2022, then crashed 38.35% in 2024.
  • Fulcrum Therapeutics' Research & Development stood at $18.9 million in 2021, then decreased by 1.83% to $18.6 million in 2022, then increased by 2.33% to $19.0 million in 2023, then plummeted by 38.35% to $11.7 million in 2024, then surged by 31.61% to $15.4 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Research & Development are $15.4 million (Q4 2025), $14.3 million (Q3 2025), and $13.0 million (Q2 2025).